PMID- 35842684
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220729
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jul 16
TI  - One-year follow-up study after patients with severe COVID-19 received human 
      umbilical cord mesenchymal stem cells treatment.
PG  - 321
LID - 10.1186/s13287-022-02972-3 [doi]
LID - 321
AB  - BACKGROUND: The novel coronavirus is still mutating, and the pandemic continues. 
      Meanwhile, many COVID-19 survivors have residual postinfection clinical 
      manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been 
      shown to be effective in the early stages of COVID-19. OBJECTIVES: The aim of 
      this study was to investigate long-term safety and efficacy of treatment in 
      patients with severe COVID-19 patients who had received hUC-MSCs therapy. 
      METHODS: Twenty-five discharged patients who had severe COVID-19 (including the 
      standard treatment group and the standard treatment plus hUC-MSCs group) were 
      enrolled in a 1-year follow-up. The assessment considered adverse effects 
      (including effects on liver and kidney function, coagulation, ECG, tumor marker, 
      and so on), pulmonary function, St George's Respiratory Questionnaire (SGRQ), 
      postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), 
      malondialdehyde (MDA), H(2)S, carnitine, and N-6 long-chain polyunsaturated fatty 
      acids (N-6 LC-PUFAs). MEASUREMENTS AND MAIN RESULTS: Pulmonary ventilation 
      function had significantly improved at the 1-year follow-up in both the hUC-MSCs 
      group and the control group compared with the 3-month follow-up (P < 0.01). 
      Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. 
      The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% 
      [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of 
      KL-6 was significantly lower in the hUC-MSCs group (2585.5 +/- 186.5 U/ml) than in 
      the control group (3120.7 +/- 158.3 U/ml) (P < 0.001). Compared with the control 
      group, the hUC-MSCs group had a lower level of MDA (9.27 +/- 0.54 vs. 
      9.91 +/- 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the 
      hUC-MSCs treatment group at 1 year after discharge. CONCLUSIONS: Intravenous 
      transplantation of hUC-MSCs was a safe approach in the long term in the treatment 
      of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on 
      postinfection sequelae in COVID-19 survivors. TRIAL REGISTRATION: Chinese 
      Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 
      2020-Retrospectively registered, http://www.medresman.org.
CI  - (c) 2022. The Author(s).
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Pulmonary and Critical Medicine, the Second Affiliated Hospital of 
      Nanjing Medical University, Nanjing, 210011, Jiangsu, China.
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Zheng, You
AU  - Zheng Y
AD  - Department of Nephrology, Huangshi Hospital of Traditional Chinese Medicine, 
      Huangshi, 435000, Hubei, China.
FAU - Cheng, Zhi
AU  - Cheng Z
AD  - Department of Critical Care Medicine, the Second Affiliated Hospital of Nanjing 
      Medical University, Nanjing, 210011, Jiangsu, China.
FAU - Ji, Ningfei
AU  - Ji N
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Nanjing Medical University, Nanjing, 210029, China.
FAU - Niu, Changming
AU  - Niu C
AD  - Department of Critical Care Medicine, the Second Affiliated Hospital of Nanjing 
      Medical University, Nanjing, 210011, Jiangsu, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Jiangsu Cell Tech Medical Research Institute, Nanjing, 211166, Jiangsu, China.
FAU - Huang, Tingrong
AU  - Huang T
AD  - Department of Nephrology, Huangshi Hospital of Traditional Chinese Medicine, 
      Huangshi, 435000, Hubei, China.
FAU - Li, Ruyou
AU  - Li R
AD  - Department of Respiratory Medicine, Huangshi Central Hospital, Huangshi, 435000, 
      Hubei, China.
FAU - Huang, Mao
AU  - Huang M
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Nanjing Medical University, Nanjing, 210029, China.
FAU - Chen, Xiaolin
AU  - Chen X
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Shu, Lei
AU  - Shu L
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Wu, Mingjing
AU  - Wu M
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Deng, Kaili
AU  - Deng K
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Wei, Jing
AU  - Wei J
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Wang, Xueli
AU  - Wang X
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Cao, Yang
AU  - Cao Y
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Yan, Jiaxin
AU  - Yan J
AD  - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical 
      University, Nanjing, 211166, Jiangsu, China.
FAU - Feng, Ganzhu
AU  - Feng G
AUID- ORCID: 0000-0003-3926-1753
AD  - Department of Pulmonary and Critical Care Medicine, the Second Affiliated 
      Hospital of Nanjing Medical University, No. 121 Jiangjiayuan Rd, Gulou District, 
      Nanjing, 210011, Jiangsu, China. fenggz163@163.com.
LA  - eng
SI  - ChiCTR/ChiCTR2000031494
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220716
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - *COVID-19/therapy
MH  - Fatigue
MH  - Follow-Up Studies
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - *Mesenchymal Stem Cells
MH  - Umbilical Cord
PMC - PMC9288258
OTO - NOTNLM
OT  - 1-Year follow-up
OT  - Coronavirus disease 2019 (COVID-19)
OT  - Human umbilical cord mesenchymal stem cells (h-UC-MSCs)
OT  - Safety
OT  - Sequelae
COIS- The authors declare that they have no competing interests.
EDAT- 2022/07/17 06:00
MHDA- 2022/07/20 06:00
PMCR- 2022/07/16
CRDT- 2022/07/16 23:30
PHST- 2022/02/09 00:00 [received]
PHST- 2022/05/22 00:00 [accepted]
PHST- 2022/07/16 23:30 [entrez]
PHST- 2022/07/17 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/07/16 00:00 [pmc-release]
AID - 10.1186/s13287-022-02972-3 [pii]
AID - 2972 [pii]
AID - 10.1186/s13287-022-02972-3 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2022 Jul 16;13(1):321. doi: 10.1186/s13287-022-02972-3.